Abemaciclib in Combination With Endocrine Therapy for Patients With Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer: A Phase 1b Study

BACKGROUND: Cyclin-dependent kinases (CDK) 4 and 6 regulate G1 to S cell cycle progression and are often altered in cancers. Abemaciclib is a selective inhibitor of CDK4 and CDK6 approved for administration on a continuous dosing schedule as monotherapy or as combination therapy with an aromatase in...

Descripción completa

Detalles Bibliográficos
Autores principales: Tolaney, Sara M., Beeram, Muralidhar, Beck, J. Thaddeus, Conlin, Alison, Dees, E. Claire, Puhalla, Shannon L., Rexer, Brent N., Burris, Howard A., Jhaveri, Komal, Helsten, Teresa, Becerra, Carlos, Kalinsky, Kevin, Moore, Kathleen N., Manuel, Allison M., Lithio, Andrew, Price, Gregory L., Chapman, Sonya C., Litchfield, Lacey M., Goetz, Matthew P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8868006/
https://www.ncbi.nlm.nih.gov/pubmed/35223458
http://dx.doi.org/10.3389/fonc.2021.810023

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8868006/
https://www.ncbi.nlm.nih.gov/pubmed/35223458
http://dx.doi.org/10.3389/fonc.2021.810023

Ejemplares similares